Compare Sana Biotechnology Inc (SANA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vale SA — how do they compare? Sana Biotechnology Inc trades at $3.8 (market cap $1.13B), while Vale SA trades at $14.41 (market cap $61.97B). The key difference: Vale SA is far larger — about 54.8× Sana Biotechnology Inc's market cap, and Vale SA pays a 8.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VALE | |
|---|---|---|
Market Cap | $1.13B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $17.82 |
52-Week Low | $2.68 | $9.71 |
Enterprise Value | $1.05B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
VALE trades at $14.465, down 2.85% today, with a bearish technical signal and recent earnings misses. The stock shows weak profitability with a net margin of 5.11% and declining revenue from $38.4B in 2025 to a projected $41.2B in 2026. Analyst consensus is mixed with a $16.79 price target, while cash flow improved to $2.42B in 2025. News highlights Q2 2026 earnings focusing on copper growth and cost discipline.
Outlook remains cautious due to earnings volatility and rising costs, but the base metals segment growth offers upside. Key risks include operational challenges and debt levels. The stock presents a value opportunity if cost controls improve, but investors should weigh analyst hold ratings against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
